[Chemotherapy against pulmonary metastasis from uterine cervical carcinoma]

The eligibilities for chemotherapy, prognostic factors and effects of chemotherapy were evaluated in pulmonary metastasis from uterine cervical carcinoma. There was no difference in median survival between patients treated with surgery and those with chemotherapy. The mediastinal lymph node involvement and vascular invasion were demonstrated to be important prognostic factors in patients treated with surgery, and it was suggested that systemic chemotherapy should be given to the patients with mediastinal lymph node involvement. The median survivals of patients treated with chemotherapy were 12.3 months in patients with pulmonary metastasis alone and 5 months in those with both pulmonary and other visceral metastasis, respectively. Responders to chemotherapy survived longer than non-responders. Overall response rate was 42.7% (44/103), and the response rate of MDU (Mitomycin C+Dextran sulfate+Urokinase) (62.3%) was higher than other chemotherapeutic regimens, which suggested that appropriate chemotherapy would prolong the survival of patients with pulmonary metastasis from uterine carcinoma.